For research use only. Not for therapeutic Use.
BAY-728（Cat No.:I041406）is a selective inhibitor of the protein kinase B (AKT) pathway, which plays a critical role in regulating cell survival, growth, and metabolism. By targeting AKT, BAY-728 disrupts the signaling pathways that contribute to uncontrolled cell proliferation, making it a potential therapeutic candidate in cancer treatment. Its mechanism of action involves blocking AKT activation, thereby inhibiting tumor cell growth and survival. Research is ongoing to assess its efficacy in treating various cancers, particularly those driven by hyperactivation of the AKT pathway, and its potential for combination therapies.
| Synonyms | N-[(2S)-1-[[5-[(4-cyanophenyl)methyl]-1,3,4-thiadiazol-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-(trifluoromethyl)cyclohexane-1-carboxamide |
| Molecular Formula | C24H28F3N5O2S |
| Purity | ≥95% |
| IUPAC Name | N-[(2S)-1-[[5-[(4-cyanophenyl)methyl]-1,3,4-thiadiazol-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-(trifluoromethyl)cyclohexane-1-carboxamide |
| InChI | InChI=1S/C24H28F3N5O2S/c1-15(2)12-18(29-21(34)23(24(25,26)27)10-4-3-5-11-23)20(33)30-22-32-31-19(35-22)13-16-6-8-17(14-28)9-7-16/h6-9,15,18H,3-5,10-13H2,1-2H3,(H,29,34)(H,30,32,33)/t18-/m0/s1 |
| InChIKey | LXRBPWHQMGKMRT-SFHVURJKSA-N |
| SMILES | CC(C)C[C@@H](C(=O)NC1=NN=C(S1)CC2=CC=C(C=C2)C#N)NC(=O)C3(CCCCC3)C(F)(F)F |
